Chelsie O'Connor
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Chelsie O'Connor has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
- Desmond Yip
Department of Medical Oncology, The Canberra Hospital, Garran, ACT, Australia
3 shared publications - Venessa Chin
Translational Genomics Program, Garvan Institute of Medical Research, Sydney, Australia
3 shared publications Adnan Nagrial
The Kinghorn Cancer Centre, The Garvan Institute of Medical Research, Sydney, Australia
2 shared publications- Andrew Victor Biankin
Wolfson Wohl Cancer Research Centre, School of Cancer Sciences, College of Medical, Veterinary and Life Sciences, University of Glasgow
2 shared publications Katrin Marie Sjoquist
NHMRC Clinical Trials Centre, University of Sydney and Cancer Care Centre, St. George Hospital, Sydney, Australia
2 shared publications- Katrin Sjoquist
NHMRC Clinical Trials Centre, University of Sydney, 119-143 Missenden Rd, Sydney, NSW 2050, Australia
2 shared publications
Latest Publications
- 20 January 2015
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 33 (3_suppl) , 348
Role of chemoradiation in locally advanced pancreatic cancer: A systematic review and meta-analysis.
348 Background: The role of combined modality therapy in the management of locally advanced pancreatic cancer (LAPC) is uncertain. Current guidelines recommend combined modality therapy for select patients. We sought to review the evidence for combined modality versus single modality therapy in LAPC. We performed a systematic review and meta-analysis of randomised controlled trials (RCT) comparing chemoradiation versus chemotherapy alone as well as chemoradiation versus radiation alone in patients with LAPC. Methods: We searched MEDLINE, EMBASE and CENTRAL from inception to Oct 2013 for RCTs comparing chemotherapy alone versus chemotherapy plus radiation and radiation alone versus chemotherapy plus radiation. We also searched abstracts of major cancer meetings from 1990 to 2013. The primary outcome was overall survival (OS). Secondary outcomes included progression-free survival (PFS), response rate and adverse events. Hazard ratios (HR), confidence intervals (CI) and p-values (p) were estimated with a random-effects model due to the heterogeneity of included studies using Revman 5.3. Results: We included 7 eligible trials including 753 patients. Induction chemotherapy was delivered prior to randomisation in one study. Chemoradiation versus chemotherapy (n= 5 studies) did not improve PFS (HR 1.02, 95% CI 0.87 - 1.20, p = 0.80) or OS (HR 0.91, 95% CI 0.64 - 1.31, p = 0.61). However, chemoradiation versus radiation (n=2 studies) improved PFS (HR 0.63, 95% CI 0.41 - 0.96, p = 0.03) and OS (HR 0.65, 95% CI 0.43 – 0.96, p = 0.03). There was significant statistical heterogeneity in the included studies and subsequently wide confidence intervals in the pooled results. This is most likely due to the small participant numbers in each study. Adverse events were more frequent in the chemoradiation arms. Response rates were assessed in only two studies. Conclusions: Chemoradiation is not superior to chemotherapy alone in LAPC, but may be superior to radiation alone. The studies were small with significant heterogeneity. Combined modality therapy results in increased adverse events. Our results do not provide evidence for a universal standard of care, thus more studies of combined modality therapy in LAPC are needed.
- 20 January 2015
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 33 (3_suppl) , 348
Role of chemoradiation in locally advanced pancreatic cancer: A systematic review and meta-analysis.
348 Background: The role of combined modality therapy in the management of locally advanced pancreatic cancer (LAPC) is uncertain. Current guidelines recommend combined modality therapy for select patients. We sought to review the evidence for combined modality versus single modality therapy in LAPC. We performed a systematic review and meta-analysis of randomised controlled trials (RCT) comparing chemoradiation versus chemotherapy alone as well as chemoradiation versus radiation alone in patients with LAPC. Methods: We searched MEDLINE, EMBASE and CENTRAL from inception to Oct 2013 for RCTs comparing chemotherapy alone versus chemotherapy plus radiation and radiation alone versus chemotherapy plus radiation. We also searched abstracts of major cancer meetings from 1990 to 2013. The primary outcome was overall survival (OS). Secondary outcomes included progression-free survival (PFS), response rate and adverse events. Hazard ratios (HR), confidence intervals (CI) and p-values (p) were estimated with a random-effects model due to the heterogeneity of included studies using Revman 5.3. Results: We included 7 eligible trials including 753 patients. Induction chemotherapy was delivered prior to randomisation in one study. Chemoradiation versus chemotherapy (n= 5 studies) did not improve PFS (HR 1.02, 95% CI 0.87 - 1.20, p = 0.80) or OS (HR 0.91, 95% CI 0.64 - 1.31, p = 0.61). However, chemoradiation versus radiation (n=2 studies) improved PFS (HR 0.63, 95% CI 0.41 - 0.96, p = 0.03) and OS (HR 0.65, 95% CI 0.43 – 0.96, p = 0.03). There was significant statistical heterogeneity in the included studies and subsequently wide confidence intervals in the pooled results. This is most likely due to the small participant numbers in each study. Adverse events were more frequent in the chemoradiation arms. Response rates were assessed in only two studies. Conclusions: Chemoradiation is not superior to chemotherapy alone in LAPC, but may be superior to radiation alone. The studies were small with significant heterogeneity. Combined modality therapy results in increased adverse events. Our results do not provide evidence for a universal standard of care, thus more studies of combined modality therapy in LAPC are needed.
- 20 May 2014
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 32 (15_suppl) , e15209
Targeted therapies in the treatment of advanced pancreatic adenocarcinoma (PC): A systematic review and meta-analysis of randomized trials.
E15209 Background: PC has a uniformly poor prognosis and has marked genetic heterogeneity. Although some progress has been made recently in the treatment for advanced disease, the role of targeted therapy (TT) remains controversial. We aimed to better define the role of TTs in PC by performing a systematic review and meta-analysis of relevant randomised controlled trials (RCT). Methods: RCTs with at least one treatment arm containing a TT were identified from systematically searching databases (MEDLINE, EMBASE, CENTRAL) and conference abstracts from Jan 1996 - Dec 2013. We considered monoclonal antibodies or small molecules against specific receptors or signaling pathways as TTs. The primary outcome was overall survival (OS) and secondary outcomes were progression free survival (PFS), response rates (RR), adverse events (AE) and quality of life (QOL). Hazard ratios (HR), confidence intervals (CI) and p-values were analysed using a fixed effects model with Revman 5.2. Results: 23 trials with a total of 6,9...
- 20 May 2014
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 32 (15_suppl) , e15209
Targeted therapies in the treatment of advanced pancreatic adenocarcinoma (PC): A systematic review and meta-analysis of randomized trials.
E15209 Background: PC has a uniformly poor prognosis and has marked genetic heterogeneity. Although some progress has been made recently in the treatment for advanced disease, the role of targeted therapy (TT) remains controversial. We aimed to better define the role of TTs in PC by performing a systematic review and meta-analysis of relevant randomised controlled trials (RCT). Methods: RCTs with at least one treatment arm containing a TT were identified from systematically searching databases (MEDLINE, EMBASE, CENTRAL) and conference abstracts from Jan 1996 - Dec 2013. We considered monoclonal antibodies or small molecules against specific receptors or signaling pathways as TTs. The primary outcome was overall survival (OS) and secondary outcomes were progression free survival (PFS), response rates (RR), adverse events (AE) and quality of life (QOL). Hazard ratios (HR), confidence intervals (CI) and p-values were analysed using a fixed effects model with Revman 5.2. Results: 23 trials with a total of 6,9...
- Open Access
- 1 January 2014
- Published by Baishideng Publishing Group Inc. in World Journal of Gastroenterology
- Vol. 20 (24) , 7849-7863
Personalising pancreas cancer treatment: When tissue is the issue
The treatment of advanced pancreatic cancer has not moved much beyond single agent gemcitabine until recently when protocols such as FOLFIRINOX (fluorouracil, leucovorin, irinotecan and oxaliplatin) and nab-paclitaxel-gemcitabine have demonstrated some improved outcomes. Advances in technology especially in massively parallel genome sequencing has progressed our understanding of the biology of pancreatic cancer especially the candidate signalling pathways that are involved in tumourogenesis and disease course. This has allowed identification of potentially actionable mutations that may be targeted by new biological agents. The heterogeneity of pancreatic cancer makes tumour tissue collection important with the aim of being able to personalise therapies for the individual as opposed to a one size fits all approach to treatment of the condition. This paper reviews the developments in this area of translational research and the ongoing clinical studies that will attempt to move this into the everyday oncology practice.
- 1 January 2014
- Published by Baishideng Publishing Group Inc. in World Journal of Gastroenterology
- Vol. 20 (24) , 7849-7863
Open AccessPersonalising pancreas cancer treatment: When tissue is the issue
The treatment of advanced pancreatic cancer has not moved much beyond single agent gemcitabine until recently when protocols such as FOLFIRINOX (fluorouracil, leucovorin, irinotecan and oxaliplatin) and nab-paclitaxel-gemcitabine have demonstrated some improved outcomes. Advances in technology especially in massively parallel genome sequencing has progressed our understanding of the biology of pancreatic cancer especially the candidate signalling pathways that are involved in tumourogenesis and disease course. This has allowed identification of potentially actionable mutations that may be targeted by new biological agents. The heterogeneity of pancreatic cancer makes tumour tissue collection important with the aim of being able to personalise therapies for the individual as opposed to a one size fits all approach to treatment of the condition. This paper reviews the developments in this area of translational research and the ongoing clinical studies that will attempt to move this into the everyday oncology practice.
- 24 June 2013
- Published by Wiley in Cochrane Database of Systematic Reviews
- No. 6
Pharmacologic and radiotherapeutic interventions for advanced pancreatic cancer
- 24 June 2013
- Published by Wiley in Cochrane Database of Systematic Reviews
- No. 6
Pharmacologic and radiotherapeutic interventions for advanced pancreatic cancer